Consequence of COVID-19 on allergic asthma outcomes: a systematic review and meta-analysis

Main Article Content

Xiaoqing Li
Dandan Sheng
Kai Chen
Qiao Wang


COVID-19, Allergy, Asthma, SARS-Cov2, Risk


Asthma is a common chronic lung disease, and COVID-19 pandemic as a respiratory viral disease led to lung infection and resulted in millions of deaths. So, the impact of COVID-19 on asthma outcomes and the risk of being infected or hospitalized should be clarified. Systematic review and meta-analysis on the outcomes and risk of asthma for people with COVID-19 was done by searching electronic databases between 1 December 2019 and 31 July 2023. A total of 48 studies from 27 countries spread across all continents were included in the review. The prevalence of asthma among COVID-19 patients was 7.9%, and the analysis demonstrated a 16.5% reduction in the risk ratio for acquiring COVID-19 among subjects with asthma compared to those without asthma. There was no statistically significant difference in hospitalization risk, ICU admission risk, and death risk for COVID-19 patients with no asthma compared to those with asthma. The risk of death from COVID-19 was similar between nonasthmatics and asthmatics. The findings indicated that subjects with asthma may be at a lower risk of having infection with COVID-19 compared to those without asthma, but they have a similar risk of hospitalization and mortality.

Abstract 142 | PDF Downloads 169 HTML Downloads 0 XML Downloads 3


1. Masoume AS, Mehrabi NE, Shamsadin AS. Study effect of Ocimum basilicum seeds on mucus production and cytokine gene expression in allergic asthma mice model. Revue française d’allergologie. 2018;58(7):489–493. 10.1016/j.reval.2018.08.003

2. Nasab EM, Athari SM, Motlagh B, Athari SS. Effects of oral administration of Ocimum basilicum on goblet cell hyperplasia and upstream cytokine gene expression in allergic asthma. Revue française d’allergologie 2020;60:64–68. 10.1016/j.reval.2019.02.226

3. Hajimohammadi B, Athari SM, Abdollahi M, Vahedi G, Athari SS. Oral Administration of Acrylamide Worsens the Inflammatory Responses in the Airways of Asthmatic Mice through Agitation of Oxidative Stress in the Lungs. Frontiers in Immunol 2020;11:1940. 10.3389/fimmu.2020.01940

4. Entezar MN, Seyyed SA. COVID-19 Cytokine Storm Complications in Asthmatic Patients. The Open Public Health J 2020;13:625–626. 10.2174/1874944502013010625

5. Entezar MN, Siamak H, Bahram Y, Seyyed SA. Acute upper limb ischemia in a patient with COVID-19: A case report. Annals of Vasc Surg 2021;77:83–85. 10.1016/j.avsg.2021.07.007

6. Entezar MN, Siamak H, Seyyed SA. Right atrial clot and pulmonary embolism in a patient with COVID-19: A case report. Radiology Case Reports 2021;16:3392–3395. 10.1016/j.radcr.2021.08.015

7. Entezar MN, Seyyed SA. The first report of 2:1 atrioventricular block following COVID-19 vaccination. Clin Case Rep. 2022;10:e05797. 10.1002/ccr3.5797

8. Ling Q, Entezar MN, Seyyede MA, Seyyed SA. Mitochondria signaling pathways in allergic asthma. J Investig Med 2022;70(4):863–882. 10.1136/jim-2021-002098

9. Entezar Mehrabi Nasab, Seyyed Shamsadin Athari. Reporting complete heart block in a patient with polyarteritis nodosa after COVID-19 vaccination. ESC Heart Failure 2023;10(2):1418–1421. 10.1002/ehf2.14227

10. Dong W, Entezar MN, Seyyed SA. Study effect of Baicalein encapsulated/loaded Chitosan-nanoparticle on allergic Asthma pathology in mouse model. Saudi J Biol Sci 2021;28:4311–4317. 10.1016/j.sjbs.2021.04.009

11. Jinan J, Entezar MN, Seyyede MA, Seyyed SA. Effects of vitamin E and selenium on allergic rhinitis and asthma pathophysiology. Respiratory Physiology & Neurobiology 2021;286:103614. 10.1016/j.resp.2020.103614

12. Zhiwei W, Entezar MN, Poonam A, Seyyed SA. Study effect of probiotics and prebiotics on treatment of OVA-LPS-induced of allergic asthma inflammation and pneumonia by regulating the TLR4/NF-kB signaling pathway. Journal of Translational Medicine 2022;20:130. 10.1186/s12967-022-03337-3

13. Anthony PS, Sabine MA, Gian LDT, Christine RJ. Asthma and COVID-19 risk: a systematic review and meta--analysis. Eur Respir J 2022;59:2101209. 10.1183/13993003.01209-2021

14. Ouzzani M, Hammady H, Fedorowicz Z, et al. Rayyan–a web and mobile app for systematic reviews. Syst Rev 2016;5:210. 10.1186/s13643-016-0384-4

15. Wells G, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-analyses. 2020.

16. Caminati M, Vultaggio A, Matucci A, et al. Asthma in a large COVID-19 cohort: prevalence, features, and determinants of COVID-19 disease severity. Respir Med 2021;176:106261. 10.1016/j.rmed.2020.106261

17. Caliskan T, Saylan B. Smoking and comorbidities are associated with COVID-19 severity and mortality in 565 patients treated in Turkey: a retrospective observational study. Rev Assoc Med Bras 2020;66:1679–1684. 10.1590/1806-9282.66.12.1679

18. Patone M, Thomas K, Hatch R, et al. Mortality and critical care unit admission associated with the SARS-CoV-2 lineage B.1.1.7 in England: an observational cohort study. Lancet Infect Dis 2021;21:1518–1528. 10.1016/S1473-3099(21)00318-2

19. Cao L, Lee S, Krings JG, et al. Asthma in patients with suspected and diagnosed coronavirus disease 2019. Annal Allergy Asthma Immunol 2021;126:535–541. 10.1016/j.anai.2021.02.020

20. Green I, Merzon E, Vinker S, et al. COVID-19 susceptibility in bronchial asthma. J Allergy Clin Immunol Pract 2021;9:684–692. 10.1016/j.jaip.2020.11.020

21. Bedolla-Barajas M, Morales-Romero J, Bedolla-Pulido TR, et al. Low prevalence of asthma in Mexican children and adults with a positive rtRT-PCR test for SARS-CoV-2: a cross-sectional study during the 2020 pandemic. Al Immuno 2021;49:1–7. 10.15586/aei.v49i3.7

22. Ho KS, Howell D, Rogers L, et al. The relationship between asthma, eosinophilia, and outcomes in coronavirus disease 2019 infection. Ann Allergy Asthma Immunol 2021;127:42–48. 10.1016/j.anai.2021.02.021

23. Wark PAB, Pathinayake PS, Kaiko G, et al. ACE2 expression is elevated in airway epithelial cells from older and male healthy individuals but reduced in asthma. Respirology 2021;26:442–451. 10.1111/resp.14003

24. Ramakrishnan S, Nicolau DV, Langford B, et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respir Med 2021;9:763–772. 10.1016/S2213-2600(21)00212-5

25. Yu L-M, Bafadhel M, Dorward J, et al. Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet. 2021;398(10303):843–855. 10.1016/S0140-6736(21)01744-X

26. Schönfeld D, Arias S, Bossio JC, et al. Clinical presentation and outcomes of the first patients with COVID-19 in Argentina: results of 207079 cases from a national database. PLoS One 2021;16:e0246793. 10.1371/journal.pone.0246793

27. Louie T, Kwan B, Susanto C, et al. Respiratory failure, clinical course and community management of COVID-19 patients in a large Australian cohort. Intern Med J 2021;51:334–340. 10.1111/imj.15206

28. Je D, O’Brolchain A, Ulett KB, et al. Demographics, clinical characteristics and outcomes among 197 patients with COVID-19 in the Gold Coast area. Intern Med J 2021;51:666–672. 10.1111/imj.15260

29. Calmes D, Graff S, Maes N, et al. Asthma and COPD are not risk factors for ICU stay and death in case of SARS-CoV2-infection. J Allergy Clin Immunol Pract 2021; 9:160–169. 10.1016/j.jaip.2020.09.044

30. Tutiya C, Mello F, Chaccur G, et al. Risk factors for severe and critical Covid-19 in pregnant women in a single center in Brazil. J Matern Fetal Neonatal Med. 2022;35(25):5389–5392. 10.1080/14767058.2021.1880561

31. Guan W-J, Liang W-H, Shi Y, et al. Chronic respiratory diseases and the outcomes of COVID-19: a nationwide retrospective cohort study of 39,420 cases. J Allergy Clin Immunol Pract 2021;9:2645–2655. 10.1016/j.jaip.2021.02.041

32. Wang J, Guo S, Zhang Y, et al. Clinical features and risk factors for severe inpatients with COVID-19: a retrospective study in China. PLoS One 2020;15:e0244125. 10.1371/journal.pone.0244125

33. Zhang JJ, Cao YY, Dong X, et al. Distinct characteristics of COVID-19 patients with initial rRT-PCR-positive and rRT-PCR-negative results for SARS-CoV-2. Allergy 2020;75:1809–1812. 10.1111/all.14316

34. Hansen ESH, Moeller AL, Backer V, et al. Severe outcomes of COVID-19 among patients with COPD and asthma. ERJ Open Res 2021;7:594–2020. 10.1183/23120541.00594-2020

35. Yordanov Y, Dinh A, Bleibtreu A, et al. Clinical characteristics and factors associated with hospital admission or death in 43 103 adult outpatients with coronavirus disease 2019 managed with the Covidom telesurveillance solution: a prospective cohort study. Clin Microbiol Infect 2021; 27;1158–1166. 10.1016/j.cmi.2021.04.010

36. Beurnier A, Jutant EM, Jevnikar M, et al. Characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who require hospitalisation. Eur Respir J 2020; 56:2001875. 10.1183/13993003.01875-2020

37. Ashinyo ME, Duti V, Dubik SD, et al. Clinical characteristics, treatment regimen and duration of hospitalization among COVID-19 patients in Ghana: a retrospective cohort study. Pan Afr Med J 2020;37:9. 10.11604/pamj.supp.2020.37.1.25718

38. Lombardi C, Roca E, Bigni B, et al. Clinical course and outcomes of patients with asthma hospitalized for severe acute respiratory syndrome coronavirus 2 pneumonia: a single--center, retrospective study. Ann Allergy Asthma Immunol 2020;125:707–709. 10.1016/j.anai.2020.07.029

39. Kipourou DK, Leyrat C, Alsheridah N, et al. Probabilities of ICU admission and hospital discharge according to patient characteristics in the designated COVID-19 hospital of Kuwait. BMC Public Health 2021;21:799. 10.1186/s12889-021-10759-z

40. Almazeedi S, Al-Youha S, Jamal MH, et al. Characteristics, risk factors and outcomes among the first consecutive 1096 patients diagnosed with COVID-19 in Kuwait. EClinicalMedicine 2020;24:100448. 10.1016/j.eclinm.2020.100448

41. Aveyard P, Gao M, Lindson N, et al. Association between pre-existing respiratory disease and its treatment, and severe COVID-19: a population cohort study. Lancet Respir Med, 2021;9:909–923. 10.1016/S2213-2600(21)00095-3

42. Martos-Benítez FD, Soler-Morejón CD, García-Del Barco D. Chronic comorbidities and clinical outcomes in patients with and without COVID-19: a large population-based study using national administrative healthcare open data of Mexico. Intern Emerg Med 2021;16:1507–1517. 10.1007/s11739-020-02597-5

43. Murillo-Zamora E, Hernandez-Suarez CM. Survival in adult inpatients with COVID-19. Public Health 2021;190: 1–3. 10.1016/j.puhe.2020.10.029

44. Nystad W, Hjellvik V, Larsen IK, et al. Underlying conditions in adults with COVID-19. Tidsskr Nor Laegeforen 2020;140(13).

45. Valverde-Monge M, Cañas JA, Barroso B, et al. Eosinophils and chronic respiratory diseases in hospitalized COVID-19 patients. Front Immunol 2021;12:668074. 10.3389/fimmu.2021.668074

46. Lemus Calderon JA, Beneyto Martin P, Guzmán Rodriguez G, et al. Differentiating characteristics of patients with asthma in the severe acute respiratory syndrome coronavirus 2 infection. Ann Allergy Asthma Immunol 2020;126:92–93. 10.1016/j.anai.2020.09.004

47. Gude-Sampedro F, Fernández-Merino C, Ferreiro L, et al. Development and validation of a prognostic model based on comorbidities to predict COVID-19 severity: a population-based study. Int J Epidemiol 2021;50:64–74. 10.1093/ije/dyaa209

48. Castilla J, Guevara M, Miqueleiz A, et al. Risk factors of infection, hospitalization and death from SARS-CoV-2: a population-based cohort study. J Clin Med 2021;10:2608. 10.3390/jcm10122608

49. Garcia-Pachon E, Zamora-Molina L, Soler-Sempere MJ, et al. Asthma prevalence in patients with SARS-CoV-2 infection detected by RT-PCR not requiring hospitalization. Respir Med 2020;171:106084. 10.1016/j.rmed.2020.106084

50. Yang JM, Koh HY, Moon SY, et al. Allergic disorders and susceptibility to and severity of COVID-19: a nationwide cohort study. J Allergy Clin Immunol 2020;146:790–798. 10.1016/j.jaci.2020.08.008

51. Lee SC, Son KJ, Han CH, et al. Impact of comorbid asthma on severity of coronavirus disease (COVID-19). Sci Rep 2020;10:21805. 10.1038/s41598-020-77791-8

52. Kim S-J, Jung C-G, Lee JY, et al. Characterization of asthma and risk factors for delayed SARS-CoV-2 clearance in adult COVID-19 inpatients in Daegu. Allergy 2021;76:918–921. 10.1111/all.14609

53. Choi YJ, Park J-Y, Lee HS, et al. Effect of asthma and asthma medication on the prognosis of patients with COVID-19. Eur Respir J 2021;57:2002226. 10.1183/13993003.02226-2020

54. Ahlström B, Frithiof R, Hultström M, et al. The Swedish COVID-19 intensive care cohort: risk factors of ICU admission and ICU mortality. Acta Anaesthesiol Scand 2021;65:525–533. 10.1111/aas.13781

55. Bergman J, Ballin M, Nordström A, et al. Risk factors for COVID-19 diagnosis, hospitalization, and subsequent all-cause mortality in Sweden: a nationwide study. Eur J Epidemiol 2021;36:287–298. 10.1007/s10654-021-00732-w

56. Arslan Y, Dogan D, Ocal N, et al. The boundaries between survival and non-survival at COVID-19: experience of tertiary care pandemic hospital. Int J Clin Pract 2021;75(9):e14461. 10.1111/ijcp.14461

57. Dennis JM, Mateen BA, Sonabend R, et al. Type 2 diabetes and COVID-19-related mortality in the critical care setting: a national cohort study in England, March–July 2020. Diabetes Care 2021;44:50–57. 10.2337/dc20-1444

58. Fong WCG, Borca F, Phan H, et al. Asthma did not increase in-hospital COVID-19-related mortality in a tertiary UK hospital. Clin Exp Allergy 2021;51:939–941. 10.1111/cea.13855

59. Baumer T, Phillips E, Dhadda A, et al. Epidemiology of the first wave of COVID-19 ICU admissions in South Wales–the interplay between ethnicity and deprivation. Front Med 2020;7:569714. 10.3389/fmed.2020.569714

60. Rosenthal JA, et al. Asthma is associated with increased risk of intubation but not hospitalization or death in coronavirus disease 2019. Ann Allergy Asthma Immunol 2020;126:93–95. 10.1016/j.anai.2020.10.002

61. Salacup G, Lo KB, Gul F, et al. Characteristics and clinical outcomes of COVID-19 patients in an underserved-inner city population: a single tertiary center cohort. J Med Virol 2021;93:416–423. 10.1002/jmv.26252

62. Liao S-Y, Petrache I, Fingerlin TE, et al. Association of inhaled and systemic corticosteroid use with coronavirus disease 2019 (COVID-19) test positivity in patients with chronic pulmonary diseases. Respir Med 2021;176:106275. 10.1016/j.rmed.2020.106275

63. Lieberman-Cribbin W, Rapp J, Alpert N, et al. The impact of asthma on mortality in patients with COVID-19. Chest 2020;158:2290–2291. 10.1016/j.chest.2020.05.575

64. Lovinsky-Desir S, Deshpande DR, De A, et al. Asthma among hospitalized patients with COVID-19 and related outcomes. J Allergy Clin Immunol 2020;146:1027–1034. 10.1016/j.jaci.2020.07.026

65. Robinson LB, Wang L, Fu X, et al. COVID-19 severity in asthma patients: a multi-center matched cohort study. J Asthma 2022;59(3). 10.1080/02770903.2020.1857396

66. Shah SJ, Barish PN, Prasad PA, et al. Clinical features, diagnostics, and outcomes of patients presenting with acute respiratory illness: A retrospective cohort study of patients with and without COVID-19. EClinicalMedicine 2020;27:100518. 10.1016/j.eclinm.2020.100518

67. Gupta R, Agrawal R, Bukhari Z, et al. Higher comorbidities and early death in hospitalized African-American patients with Covid-19. BMC Infect Dis 2021;21:78. 10.1186/s12879-021-05782-9

68. Mather JF, Mosleh W, McKay RG. The impact of asthma on in-hospital outcomes of COVID-19 patients. J Asthma. 2022;59(8):1680–1686. 10.1080/02770903.2021.1944187

69. Ferastraoaru D, Hudes G, Jerschow E, et al. Eosinophilia in asthma patients is protective against severe COVID-19 illness. J Allergy Clin Immunol Pract 2021;9:1152–1162. 10.1016/j.jaip.2020.12.045

70. Eggert L, He Z, Collins W, et al. Asthma phenotypes, associated comorbidities, and long-term symptoms in COVID-19. Allergy 2022;77:173–185. 10.1111/all.14972

71. Chhiba KD, Patel GB, Vu THT, et al. Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19. J Allergy Clin Immunol 2020; 146:307–314. 10.1016/j.jaci.2020.06.010